Zoetis (NYSE:ZTS) Given New $80.00 Price Target at Piper Sandler

Key Points

• Piper Sandler cut Zoetis’s price target from $90 to $80 while maintaining a “neutral” rating, implying roughly 7.5% upside from the stock’s $74.44 closing price.
• Zoetis posted quarterly EPS of $1.87, slightly above estimates, but revenue of $2.47 billion missed expectations and declined 0.2% year over year. Analysts maintain a consensus “Hold” rating with an average target of $110.92.
• The stock has fallen sharply from its 52-week high of $160.48, though two directors recently purchased shares near $75–$76, and institutional investors own approximately 92.8% of the company.

Zoetis (NYSE:ZTS - Get Free Report) had its target price decreased by equities research analysts at Piper Sandler from $90.00 to $80.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Piper Sandler's price target suggests a potential upside of 7.47% from the stock's current price.

A number of other equities analysts also recently issued reports on ZTS. TD Cowen decreased their price objective on Zoetis from $150.00 to $104.00 and set a "buy" rating for the company in a report on Tuesday, June 30th. Barclays dropped their target price on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 1st. Morgan Stanley set a $85.00 target price on shares of Zoetis in a research report on Friday. Stifel Nicolaus decreased their price target on shares of Zoetis from $95.00 to $85.00 and set a "hold" rating for the company in a research note on Friday, June 26th. Finally, HSBC lowered their price target on shares of Zoetis from $140.00 to $95.00 and set a "buy" rating for the company in a research report on Monday, July 6th. Seven equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $110.92.

Zoetis Stock Up 2.4%

ZTS traded up $1.78 on Monday, hitting $74.44. The company had a trading volume of 5,889,951 shares, compared to its average volume of 5,794,792. The stock has a fifty day simple moving average of $76.66 and a 200-day simple moving average of $100.58. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market capitalization of $31.21 billion, a P/E ratio of 12.27, a P/E/G ratio of 1.21 and a beta of 0.73. Zoetis has a 52-week low of $71.45 and a 52-week high of $160.48.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. The business's revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts expect that Zoetis will post 6.43 EPS for the current fiscal year.

Insider Buying and Selling at Zoetis

In related news, Director Frank A. Damelio bought 6,650 shares of the business's stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares of the company's stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 0.22% of the company's stock.

Institutional Trading of Zoetis

Institutional investors have recently bought and sold shares of the company. J. Stern & Co. LLP raised its holdings in Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company's stock worth $3,028,423,000 after acquiring an additional 23,877,416 shares during the last quarter. Norges Bank purchased a new stake in Zoetis during the 4th quarter valued at $734,425,000. Vanguard Group Inc. boosted its stake in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company's stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Flossbach Von Storch SE bought a new stake in shares of Zoetis in the 2nd quarter worth $302,601,000. Finally, BlackRock Inc. increased its holdings in shares of Zoetis by 10.8% in the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock worth $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source